IgG effector mechanisms

Chemical Immunology

Volumn 65, Issue , 1997, Pages 88-110

  Clark, Michael R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY RESPONSE; ARTICLE; COMPLEMENT FIXATION; GENETIC RECOMBINATION; GLYCOSYLATION; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; MOLECULAR SEQUENCE DATA;

EID: 0031014785     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Janeway CA Jr, Travers P: Immunobiology: The immune system in health and disease, ed 2. Oxford, Blackwell Scientific Publications, 1996.
2. Male D, Cooke A, Owen M, Trowsdale J, Champion B: Advanced Immunology, ed 3. London, Times Mirror International Publishers, 1996.
3. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C: Sequences of proteins of immunological interest. Bethesda, US Department of Health and Human Services, NIH, 1991.
4. Clark M: General introduction; in Birch JS, Lennox E (eds): Monoclonal Antibodies: Principles and Applications. New York, Wiley, 1995, pp 1-43.
5. Bruggemann M: Evolution of the rat immunoglobulin gamma heavy chain gene family. Gene 1988; 74:473-479.
6. Schneiderman RD, Hanly WC, Knight KL: Expression of 12 rabbit IgA C genes as chimeric rabbit-mouse IgA antibodies. Proc Natl Acad Sci USA 1989;86:7561-7565.
7. Warr GW, Magor KE, Higgins DA: IgY: Clues to the origins of modern antibodies. Immunol Today 1995;16:392-398.
8. Bernstein FC Koetzle TF, Williams GJB, Meyer EF Jr, Brice MD, Odger JR, Kennard O, Shimanouchi T, Tasumi M: The protein data bank: A computer-based archival file for macromolecular structures. J Mol Biol 1977;112:535-542.
9. Saul FA, Amzel LM, Poljak RJ: Preliminary refinement and structural analysis of the Fab fragment from the human immunoglobulin NEW at 2.0 Å. J Mol Biol 1978;253:585-591.
10. Marquart M, Deisenhofer J, Huber R, Palm W: Crystallographic refinement and atomic models of the intact immunoglobulin molecule Kol and its antigen-binding fragment at 3.0 Å and 1.9 Å resolution J Mol Biol 1980;141:369-375.
11. Deisenhofer J: Crystallographic refinement and atomic models of a human Fc fragment b of protein a from Staphylococcus aureus at 2.9 and 2.8 Å resolution. Biochemistry 1981;20:2361-2367.
12. Burmeister WP, Huber AH, Bjorkman PJ: Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature 1994;372:379-383.
13. Pumphrey RSH: Computer models of the human immunoglobulins. I. Shape and segmental flexibility. Immunol Today 1986;7:174-178.
14. Pumphrey RSH: Computer models of the human immunoglobulins. II. Binding sites and molecular interactions. Immunol Today 1986;7:206-211.
15. Hamers Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R: Naturally occurring antibodies devoid of light chains. Nature 1993;363:446-448.
16. Burton DR: Immunoglobulin G: Functional sites. Mol Immunol 1985;22:161-206.
17. Jefferis R, Lund J: Molecular characterisation of IgG antibody effector sites; in Clark M (ed): Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. Nottingham, Academic Titles, 1993, pp 115-126.
18. Greenwood J, Clark M: Effector functions of matched sets of recombinant human IgG subclass antibodies; in Clark M (ed): Protein Engineering of Antibody Molecules for Prophylactic and Therapeutic Applications in Man. Nottingham. Academic Titles, 1993, pp 85-100.
19. Clark M: Unconjugated antibodies as therapeutics; in Harris WF, Adair J (eds): Antibody Therapeutics. Boca Raton, CRC Press, in press.
20. Pumphrey RSH: Introduction; in Shakib F (ed): The Human IgG Subclasses. New York, Pergamon Press, 1990, pp 3-14.
21. Ward ES, Ghetie V: The effector functions of immunoglobulins: Implications for therapy. Ther Immunol 1995;2:77-94.
22. Sauer-Eriksson AE, Kleywegt GJ, Uhel M, Jones TA: Crystal-structure of the C2 fragment of streptococcal protein-G in complex with the Fc domain of human-IgG. Structure 1995;3:265-278.
23. Jefferis R: Rheumatoid factors, B cells and immunoglobulin genes. Br Med Bull 1995;51:312-331.
24. Greenspan NS, Cooper LJN: Complementarity, specificity and the nature of epitopes and paratopes in multivalent interactions. Immunol Today 1995;16:226-230.
25. van de Winkel JGJ, Capel PJA: Human IgG Fc receptor heterogeneity: Molecular aspects and Clinical implications. Immunol Today 1993;14:215-221.
26. Ravetch JV: Fc Receptors: Rubor redux. Cell 1994;78:553-560.
27. Boulianne GL, Hozumi N, Schulman MJ: Production of functional chimaeric mouse/human antibody. Nature 1984;312:643-646.
28. Neuberger MS, Williams GT, Mitchell EB, Jouhal SS, Flanagan JG, Rabbitts TH: A hapten-specific chimeric immunoglobulin E antibody which exhibits human physiological effector function. Nature 1985;314:268-271.
29. Boulianne GL, Isenman DE, Hozumi N, Shulman MJ: Biological properties of chimeric antibodies: Interaction with complement. Mol Biol Med 1987;4:37-49.
30. Bruggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-1361.
31. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H: Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA 1988;85:4852-1856.
32. Riechmann L, Clark MR, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 1988;332:323-327.
33. Gorman SD, Clark MR: Humanisation of monoclonal antibodies for therapy. Semin Immunol 1990;2:457-466.
34. Bruggemann M, Teale C, Clark M, Bindon C, Waldmann H: A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions μ, γ1, γ2a, γ2b, γ2c, ε, and α. J Immunol 1989;142:3145-3150.
35. Duncan AR, Winter G: The binding site for Clq on antibodies. Nature 1988;332:738-740.
36. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G: Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988;332:563-564.
37. Shin S, Wright A, Bonagura V, Morrison SL: Genetically-engineered antibodies: Tools for the study of diverse properties of the antibody molecule. Immunol Rev 1992;130:8-107.
38. Bindon CI, Hale G, Bruggemann M, Waldmann H: Human monoclonal IgG antibodies differ in complement activating function at the level of C4 as well as C1q. J Exp Med 1988;166:351-356.
39. Valim YML, Lachmann PJP: The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes. Clin Exp Immunol 1991;84:1-8.
40. Michaelsen TE, Garred P, Aase A: Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991;21:11-16.
41. Schneider WP, Wensel TG, Stryer L, Oi VT: Genetically engineered immunoglobulins reveal structural features controlling segmental flexibility. Proc Natl Acad Sci USA 1988;85:2509-2513.
42. Tan LK, Shopes RJ, Oi VT, Morrison SL: Influence of the hinge region on complement activation. C1q binding, and segmental flexibility in chimeric human immunoglobulins. Proc Natl Acad Sci USA 1990;87:162-166.
43. H2 domain. J Exp Med 1991; 173:1025-1028.
44. Greenwood J, Clark M, Waldmann H: Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993;23:1098-1104.
45. Tao MH, Smith RI, Morrison SL: Structural features of human immunoglobulin G that determine isotype specific differences in complement activation. J Exp Med 1993;178:661-667.
46. Brekke OH, Michaelsen TE, Aase A, Sin RH, Slic I: Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis. Eur J Immunol 1994;24:2542-2547.
47. H2 domain of chimeric human IgG1 anti-HLA DR is necessary for C1q, FcγRI and FcγRIII binding. Immunology 1995;86:319-324.
48. Michaelsen TE, Aase A, Westby C, Slie I: Enhancement of complement activation and cytolysis of human IgG3 by deletion of hinge exons. Scan J Immunol 1990;32:517-528.
49. Brekke OH, Michaelsen TE, Slie I: The structural requirements for complement activation by IgG: Does it hinge on the hinge? Immunol Today 1995;16:85-90.
50. Brekke OL, Michaelsen TE, Sin R, Sanlie I: Activation of complement by an IgG molecule without a genetic hinge. Nature 1993;363:628-630.
51. Dorai H, Wesolowski JS, Gillies SD: Role of inter-heavy and light chain disulphide bonds in the effector functions of human immunoglobulin IgG1. Mol Immunol 1992;29:1487-1491.
52. WHO: Review of the notation for the allotypic and related markers of human immunoglobulins. J Immunogenet 1976;3:357-366.
53. van Loghem E: Allotypic markers; in Shakib F (ed): Basic and Clinical Aspects of IgG Subclasses. Monogr Allergy. Basel, Karger, 1986, vol 19, pp 40-51.
54. Tax WJM, Hermes FFM, Willems RW, Capel PJA, Koene RAP: Fc receptors for mouse IgG1 on human monocytes: Polymorphism and role in antibody-induced T cell proliferation. J Immunol 1984;133:1185-1189.
55. Haagen I-A, Geerars AJG, Clark MR, van de Winkel JGJ: Interaction of human monocyte Fcγ receptors with rat IgG2b: A new indicator for the FcγRIIA (R-H131) polymorphism. J Immunol 1995;154:1852-1860.
56. Chappel MS, Isenman DE, Everett M, Xu Y, Dorrington KJ, Klein MH: Identification of the Fc gamma receptor class I binding site in human IgG through the use of recombinat IgG1/IgG2 hybrid and point-mutated antibodies. Proc Natl Acad Sci USA 1991;88:9036-9040.
57. H2 domain and is modulated by the hinge region. J Exp Med 1991;173:1483-1491.
58. Jefferis R, Lund J, Pound J: Molecular definition of interaction sites on human IgG for Fc receptors (huFcγR). Mol Immunol 1990;27:1237-1240.
59. Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R: Mapping and comparison of the interaction sites on the Fc region of the IgG responsible for the triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fcγ receptor. Mol Immunol 1992;29:633-639.
60. Huizinga TWJ, Kerst M, Nuyens JH, Vlug A, von dem Borne AEG, Roos D, Tetteroo PAT: Binding characteristics of dimeric IgG subclass complexes to human-neutrophils. J Immunol 1989;142:2359.
61. Bredius RGM, de Vries CEE, Troelestra A, van Alphen L, Weening RS, van de Winkel JGJ, Out TA: Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonised by polyclonal human IgG1 and IgG2 antibodies: Functional hFcγRIIa polymorphism to IgG2. J Immunol 1993;151:1463.
62. Burgess JK, Lindeman R, Chesterman CN, Chong BH: Single amino acid mutation of Fcγ receptor is associated with the development of heparin-induced thrombocytopenia. Br J Haematol 1995;91: 761-767.
63. Clark M, Waldmann H: T-cell killing of target cells induced by hybrid antibodies: Comparison of two bispecific monoclonal antibodies. JNCI 1987;79:1393-1401.
64. de Haas M, Koene HR, Kleijer M, de Vries E, Simsek S, van Tol MJD, Roos D, von dem Borne AEG: A triallelic FcγRIIIA polymorphism influences the binding of human-IgG by NK-cell FcγRIIIA. J Immunol 1996;156:2948-2955.
65. Vance BA, Huizinga TWJ, Wardwell K, Guyre PM: Binding of monomeric Human IgG defines an expression polymorphism of FcγRIII on large granular lymphocyte/natural killer cells. J Immunol 1993;151:6429-6439.
66. Nose M, Takano R, Nakamura S, Arata Y, Kyoguku M: Recombinant Fc of human IgG1 prepared in Escherichia coli system escapes recognition by macrophages. Int Immunol 1990;2:1109-1112.
67. Lund J, Takahashi N, Pound JD, Goodall M, Nakagawa H, Jefferis R: Oligosaccharide-protein interactions in IgG can modulate recognition by Fcγ receptors. FASEB 1994;9:115-119.
68. Isaacs JD, Clark MR, Greenwood J, Waldmann H: Therapy with monoclonal antibodies - an in vivo model for the assessment of therapeutic potential. J Immunol 1992;148:3062-3071.
69. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H: The generation of a humanised, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993;23:403-411.
70. Lifely MR, Hale C, Boyce S, Keen M, Phillips J: Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions, in press.
71. H2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1. J Exp Med 1994;180: 1087-1096.
72. Jefferis R, Lund J, Goodall M: Recognition sites on human IgG for Fc gamma receptors: The role of glycosylation. Immunol Lett 1995;44:111-117.
73. Wawrzynczak EJ, Denham S, Parnell GD, Cumber AJ, Jones P, Winter G: Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting C1q and high affinity Fc receptor binding have identical serum half-lives in the BALB/c mouse. Mol Immunol 1992;29:221.
74. Simister NE, Mostov KE: An Fc receptor structurally related to MHC class-I antigens. Nature 1989;337:184-187.
75. Israel EJ, Patel VK, Taylor SF, Marshak-Rothstein A, Simister NE: Requirement for a beta-2-microglobulin associated Fc receptor for acquisition of maternal IgG by fetal and neonatal mice. J Immunol 1995;154:6246 6251.
76. Burmeister WH, Gastinel LN, Simister NE, Blum ML, Bjorkman PJ: Crystal structure at 2.2 Å resolution of the MHC-related neonatal Fc receptor. Nature 1994;372:336-343.
77. Raghaven M, Chen MY, Gastinel LN, Bjorkman PJ: Investigation of the interaction between class I MHC-related Fc receptor and its immunoglobulin G ligand. Immunity 1994;1:303-315.
78. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ: Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995;34:14649-14657.
79. Kim JK, Tsen MF, Ghetie V, Ward ES: Localization of the site of the murine IgG 1 molecule that is involved in binding to the murine intestinal Fc receptor. Eur J Immunol 1994;24:2429-2434.
80. Story CM, Mikulska JE, Simister NE: A major histocompatibility complex class I-like Fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 1994;180:2377-2381.
81. Kristoffersen EK, Matre M: Co-localization of beta 2-microglobulin and IgG in human placental syncytiotrophoblasts. Eur J Immunol 1996;26:505-507.
82. Newman PJ: Platelet GPIIb-IIIa: Molecular variations and alloantigens. Thromb Haemost 1991; 66:111-118.
83. Vincent A, Riemersma S, Hawke S, Newsomdavis J, Brueton L: Arthrogryposis associated with antibodies inhibiting fetal acetylcholine-receptor function. Ann Neurol 1994;36:325.
84. Waldman TA, Strober W: Metabolism of immunoglobulins: Progr Allergy, Basel, Karger, 1969, vol 13, pp 1-110.
85. Brambell FWR, Hemmings WA, Morris IG: A theoretical model of gamma-globulin catabolism. Nature 1964;203:1352-1355.
86. H3 domain interfaces are required for persistence of IgG1 in the circulation of mice. Scand J Immunol 1994;40:457-465.
87. Kim JK, Tsen MF, Ghetie V, Ward ES: Identifying amino-acid residues that influence plasma-clearance of murine IgG1 fragments by site-directed mutagenesis. Eur J Immunol 1994;24:542-548.
88. Blumberg RS, Koss T, Story CM, Barisani D, Polischuk J, Lipin A, Pablo L, Green R, Simister NE: A major histocompatibility complex I-related Fc receptor for IgG on rat hepatocytes. J Clin Invest 1995;95:2397-2402.
89. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES: Abnormally short serum half-lives of IgG in beta-2-microglobulin-deficient mice. Eur J Immunol 1996;26:690-696.